Monthly Archives: June 2022

The US Food and Drug Administration has been considering whether to approve a Covid-19 vaccine produced by Novavax, an American biotechnology company.

This vaccine was given approval by the European Medicines Agency in December and has already been widely used across Europe.

It was also approved by the UKs Medicines and Healthcare products Regulatory Agency, in February.

Here we consider how the Novavax vaccine works, how it compares to other vaccines and how significant it might be in the fight against Covid-19.

The Novavax vaccine is a recombinant protein-based vaccine, which means that it involves genetic engineering technology and uses cells to produce the coronavirus spike protein.

In the case of the Novavax shot, an insect virus called a baculovirus is genetically engineered with a gene for the spike protein.

This baculovirus, Novavax explains in an online briefing document, are used to infect a type of moth cells called Sf9 cells.

The baculovirus multiplies inside the moth cells and the gene for the spike protein produces a type of genetic material called mRNA.

This mRNA causes the moth cells to produce large amounts of the coronavirus spike protein.

The proteins are purified and arranged around a tiny nanoparticle, which the company says helps your immune system recognise the target spike.

Novavax mixes these with an adjuvant, a substance that stimulates the immune system, which in this case comes from tree bark.

Once a person is injected with the vaccine, the immune system reacts against the spike proteins, resulting in a response that is protective in the event that the person is infected with the coronavirus.

The longest-established form of vaccine consists of the virus in a weakened form that is usually unable to cause disease.

In rare instances, particularly in people with compromised immune systems, such vaccines have led to illness.

Valneva, a French company, has developed a Covid-19 vaccine based on the inactivated coronavirus, although this has faced regulatory hurdles.

A later development was to use dead forms of the pathogen. While the risk of causing disease is eliminated, some such vaccines have not stimulated enough of an immune response.

The virus has to be grown in culture, which is easier for some than others, said Ian Jones, professor of virology at the University of Reading, so this can act as a technical hurdle for production.

People ride a New Jersey bus after the US government announced it would no longer enforce a mask mandate on public transport. Reuters

A third type of vaccine involves genetic engineering and results in the production of proteins from the pathogen. They include the Novavax shot and are quite widespread, Prof Jones said.

There are some for influenza. The vaccine for shingles, thats a single recombinant protein. They have a very good safety record, he said.

The technology behind recombinant protein vaccines is longer established than that used in the mRNA Covid-19 injections (such as Pfizer-BioNTech and Moderna), and the viral vector vaccines (such as Oxford-AstraZeneca and Janssen or Johnson & Johnson shots).

While mRNA and viral vector vaccines use newer technology, these vaccines have been extensively tested and found to be safe, with only rare serious side effects.

With billions of doses of different types of Covid-19 vaccine already administered around the world, it raises the question of whether we need any more vaccines.

The commonsense thing is that the more options available, the better. I know the vaccine has proved safe and effective in Europe, said David Taylor, professor emeritus of pharmaceutical and public health policy at University College London.

Prof Taylor said that, theoretically, being able to identify very specific proteins that produce an immune response, as is the approach with recombinant protein vaccines, was the ideal approach, although in practice that was not always the case.

Prof Jones said the coronavirus was still circulating and continued to cause serious illness in some people, so vaccines were still needed.

He said the Novavax vaccine might be more appealing to people who had concerns about receiving some of the existing Covid-19 injections, for example because they were based on newer technology.

They may feel reassured that this version is using a technology that has been established for many other things," Prof Jones said. "There will be a class of individuals who feel happier with this form of vaccine."

Updated: June 07, 2022, 9:36 PM

Read the original here:
What is the Novavax Covid-19 vaccine? - The National

CALGARY, AB and MOUNTAIN VIEW, Calif., June 6, 2022 /CNW/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX:WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable ingredients along with Inscripta, a global leader in automated, CRISPR-based gene editing technology, announced today that Willow has incorporated the Onyx Genome Engineering Platform into its strain engineering workflows.

Willow Biosciences Inc. Logo (CNW Group/Willow Biosciences Inc.)

Having previously been a part of Inscripta's early access program, Willow has a deep appreciation for the value that automated, parallel genome editing capability brings, especially to a lean biotech company. The integrated and intuitive interface of the benchtop Onyx instrument uses best-in-class gene editing technology, enabling scientists to rapidly perform multiplexed, whole genome CRISPR edits at the push of a button.

The Onyx platform will further accelerate Willow's genetic editing capabilities and throughput and positively impact timelines for the commercial development of its FutureGrownmolecules and subsequent reduction in time to market. Incorporation of the Onyx platform into Willow's proven workflow will enable its team to engineer strains more rapidly, giving researchers back invaluable time to focus on intelligent library design and data analysis.

"Technology advancements such as next generation sequencing have enabled researchers to read genetic information at incredible speed and depth. Inscripta's technology now enables researchers to write genetic information with the same speed and with unparalleled precision, a combination that promises endless possibilities. Willow is thrilled to seamlessly integrate Inscripta's automated, high-throughput gene editing platform to shorten our development cycles and empower our scientists to effectively harness the tremendous potential of the entire genome" said Dr. Trish Choudhary, Vice President of Research & Development at Willow Biosciences.

Story continues

"The future of the synthetic biology economy is dependent on both large and small companies innovating under increasing pressure to deliver better products, faster, and often with less resources. Willow is a great example of how a lean, yet highly innovative organization can rapidly integrate and utilize the Onyx platform," said Dr. Nandini Krishnamurthy, Vice President of Microbial Business Unit at Inscripta. "We are looking forward to working with the team at Willow to further increase their strain performance while shortening development timelines."

About Willow Biosciences Inc.

Willow develops and produces high-purity ingredients for the personal care, food and beverage, and pharmaceutical markets. Willow's FutureGrownbiotechnology platform allows large-scale production with sustainability at its core. Willow's R&D team has a proven track record of developing and commercializing bio-based manufacturing processes and products to benefit our B2B partners and their customers.

For further information, please visit http://www.willowbio.com.

About Inscripta

Inscripta is a life science technology company enabling scientists to solve some of today's most pressing challenges with the first benchtop system for genome editing. The company's automated Onyx platform, consisting of an instrument, consumables, assays, and software, makes CRISPR-based genome engineering accessible to any research lab. Inscripta supports its customers around the world from facilities in Boulder, Colorado; San Diego and Pleasanton, California; and Copenhagen, Denmark.

To learn more, visit Inscripta.com and follow @InscriptaInc. Or contact

Michael B. GonzalesVice President, Marketingmichael.gonzales@inscripta.com415.308.6467

Forward-Looking Statements

This news release may include forward-looking statements including opinions, assumptions, estimates and the Company's assessment of future plans and operations, and, more particularly, statements concerning: Willow's ability to expand genetic editing capabilities and throughput and positively impact timelines for the commercial development of its FutureGrownmolecules; and the business plan of the Company. When used in this news release, the words "will," "anticipate," "believe," "estimate," "expect," "intent," "may," "project," "should," and similar expressions are intended to be among the statements that identify forward-looking statements. The forward-looking statements are founded on the basis of expectations and assumptions made by the Company which include, but are not limited to: the success of Willow's strategic partnerships, including the development of future strategic partnerships; the financial strength of the Company; the ability of the Company to fund its business plan using cash on hand and existing resources; the market for Willow's products; the ability of the Company to obtain and retain applicable licences; the ability of the Company to obtain suitable manufacturing partners and other strategic relationships; and the successful implementation of Willow's commercialization and production strategy, generally. Forward-looking statements are subject to a wide range of risks and uncertainties, and although the Company believes that the expectations represented by such forward-looking statements are reasonable, there can be no assurance that such expectations will be realized. Any number of important factors could cause actual results to differ materially from those in the forward-looking statements including, but not limited to, risks associated with: the biotechnology industry in general; the success of the Company's research and development strategies; infringement on intellectual property; failure to benefit from partnerships or successfully integrate acquisitions; actions and initiatives of federal and provincial governments and changes to government policies and the execution and impact of these actions, initiatives and policies; competition from other industry participants; adverse U.S., Canadian and global economic conditions; adverse global events and public-health crises, including the current COVID-19 outbreak; failure to comply with certain regulations; departure of key management personnel or inability to attract and retain talent; and other factors more fully described from time to time in the reports and filings made by the Company with securities regulatory authorities. Please refer to the Company's most recent annual information form and management's discussion and analysis for additional risk factors relating to Willow, which can be accessed either on Willow's website at http://www.willowbio.com or under the Company's profile on http://www.sedar.com.

Any financial outlook and future-oriented financial information contained in this document regarding prospective financial performance, financial position, cash balances or revenue is based on assumptions about future events, including economic conditions and proposed courses of action based on management's assessment of the relevant information that is currently available. Projected operational information contains forward-looking information and is based on a number of material assumptions and factors, as are set out above. These projections may also be considered to contain future-oriented financial information or a financial outlook. The actual results of the Company's operations for any period will likely vary from the amounts set forth in these projections and such variations may be material. Actual results will vary from projected results. Readers are cautioned that any such financial outlook and future-oriented financial information contained herein should not be used for purposes other than those for which it is disclosed herein.

The forward-looking statements contained in this news release are made as of the date hereof and the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, except as required by applicable law. The forward-looking statements contained herein are expressly qualified by this cautionary statement.

Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/willow-biosciences-incorporates-inscriptas-onyx-platform-to-expand-strain-engineering-capabilities-and-throughput-301561340.html

SOURCE Willow Biosciences Inc.

Cision

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/June2022/06/c8955.html

Read more from the original source:
WILLOW BIOSCIENCES INCORPORATES INSCRIPTA'S ONYX PLATFORM TO EXPAND STRAIN ENGINEERING CAPABILITIES AND THROUGHPUT - Yahoo Finance

Thus far, researchers have not identified ancestral viruses that could have plausibly given rise to the SARS-CoV-2 virus that causes COVID-19so says a new report from the Scientific Advisory Group for the Origins (SAGO) of Novel Pathogens set up by the World Health Organization (WHO).

The report, however, notes that "the current available data on the closest related SARS-like viruses and susceptibility of many animal species to SARS-CoV-2 suggest a zoonotic source." Assuming a natural outbreak, horseshoe bats are a likely reservoir of the virus in the wild, although it could also have passed through an unknown intermediate species before infecting humans.

An alternative hypothesis is that the COVID-19 virus somehow escaped from the Wuhan Institute of Virology, whose researchers were known to be experimenting with coronaviruses. Although three of the 27 members of the SAGO objected to consideration of the "lab leak" theory for the possible origin of the COVID-19 virus, the report states that "it remains important to consider all reasonable scientific data that is available either through published or other official sources to evaluate the possibility of the introduction of SARS-CoV-2 into the human population through a laboratory incident."

Interestingly, a Chinese team reported the results of testing 1380 samples taken from the Huanan Seafood Wholesale Market, where the outbreak was first identified. None of the samples from 188 live animals sold as meat detected the presence of the COVID-19 virus, but the researchers did find it in 73 samples from the ground, sewer wells, and various containers. "Skeptics of the natural origin theory maintain the market cluster could merely be a superspreader event touched off when a person infected with a lab-escaped coronavirus visited it," noted Science back in February.

Further investigation into the lab leak hypothesis would require that the Chinese government provide "access to and review the evidence of all laboratory (both in vitro and in vivo studies) with coronaviruses including SARS-CoV-2-related viruses or close ancestors." Going forward, the SAGO would like to obtain more information about "the nature of the studies performed before the first reported COVID-19 cases in Wuhan and whether they involved reverse engineering or gain-of-function, genetic manipulation or animal studies with strains of SARS-like CoV."

WHO Director-General Tedros Adhanom Ghebreyesus sent two letters in February to Chinese Premier Li Keqiang and National Health Commission head Ma Xiaowei asking for any updates with respect to ongoing studies focused on the origins of the COVID-19 virus. However, the SAGO report notes that the Chinese government and researchers have "not provided any information related to studies conducted evaluating the laboratory hypotheses as a possible introduction into the human population."

The SAGO reports that it will remain open to "any and all scientific evidence that becomes available in the future to allow for comprehensive testing of all reasonable hypotheses," including the lab leak hypothesis.

The Chinese government's continued stonewalling of independent investigations of the origin of the COVID-19 virus strongly suggests that it has something to hide.

Link:
COVID-19 'Lab Leak' Origin Theory Merits Further Investigation, Says New WHO Report - Reason

Respiratory syncytial virus (RSV) is a common and potentially dangerous virus for which no vaccine currently exists despite decades of effort from the scientific community. Associate Professor of Biomolecular Engineering at the Baskin School of Engineering Rebecca DuBois has set out to address this pressing need. To fund her innovative approach to the development of an RSV vaccine, DuBois has been awarded the prestigious and highly competitive National Institutes of Health Research Project Grant (RO1).

RSV causes contagious cold-like symptoms that can develop into serious lung problems and lead to hospitalizations, especially in young children and older populations each year, 3 million children under five years old are hospitalized from RSV and 64 million total people are affected worldwide.The five-year, $3.8 million grant will be shared with DuBoiss collaborator Ralph Tripp at the University of Georgia and will build on both researchers' years of work studying RSV. Their overall aim is to validate their RSV vaccine in pre-clinical trials.

Theres a huge need this is a really important gap in our vaccine schedule to protect children, said DuBois, whose experience with her childs severe RSV fueled her to take on this research. I think the NIH study section reviewers liked that it's a totally different strategy than what everyone else is taking.

DuBoiss lab focuses on bioengineering the commonly overlooked RSV G protein, used by the virus to attach to host cells, to expose its vulnerable points so the hosts body can fight back.

In previous work, they have found that a region, called the central conserved domain and just 40 amino acids long, can be engineered to evoke an protective immunogenic response from the host. Additionally, a recent paper from the DuBois lab determined that this altered protein is still recognized by the bodys immune system and therefore could be effective in a vaccine.

I think since RSV has been such a difficult virus to create a vaccine for, we're innovative in that we are using structural biology to learn more about this protein and make changes to it using protein engineering to improve its immunogenicity, said Maria Juarez, a third-year Ph.D. student in the DuBois lab. Thats something that our lab has really spearheaded.

Targeting this specific region of the G protein, which remains unchanged as the virus mutates, is a cutting-edge technique in vaccine development that may allow a vaccine to continue its effectiveness as the virus mutates.

By whittling down our vaccine to this important and conserved part, and designing it so [the antigen] is exposed to our immune system in a better way, we can refocus the antibody response it wont get distracted by all the parts that arent conserved, DuBois said. Its a more strategic way to do vaccine design, instead of just targeting the whole protein and choosing one strain to target.

Juarez and the others in the DuBois lab will continue to experiment with ways to ensure that the surface of their engineered protein is structured in a way to provoke the strongest immune response. Juarez also noted that the techniques she is using to engineer the protein are cheaper and less time intensive than other methods, making future production of the vaccine scalable so it can eventually be used commercially around the world.

Once DuBoiss group has developed their vaccine, they will send it to Tripps lab to test if it creates a strong antibody response in pre-clinical models. The group expects the first vaccines to be tested in pre-clinical models by the end of 2022.

This project differs from other RSV vaccine efforts, some of which are in phase III clinical trials, in the method it uses to evoke a protective immune response. The large majority of other researchers focus on the RSV F protein, which fuses the virus and host cell membranes together to get the viruss genetic information into cells.

Eventually, the researchers anticipate that their vaccine could be combined with one that uses the F protein in order to create an even more robust immune response.

See the rest here:
Prestigious $3.8M NIH grant awarded to biomolecular engineering professor to develop an RSV vaccine - University of California, Santa Cruz

Samsung launches Solve for Tomorrow

Samsung has launched the inaugural edition of Solve for Tomorrow, a new youth-centric national education and innovation competition, which invites Indias brightest young minds to come up with innovative ideas in the areas of Education, Environment, Healthcare and Agriculture. Support will include mentoring by industry experts and the Foundation for Innovation and Technology Transfer (FITT) at Indian Institute of Technology, Delhi (IIT Delhi). For details visit http://www.samsung.com/in/solvefortomorrow

The Learn Fest 2022

Teacher skilling platform OrangeSlates has announced the second edition of The Learn Fest 2022 to be held on June 25 and 26. The theme this time is Taking NEP 2020 into classrooms. Educators interested in participating can register at https://LearnFest.OrangeSlates.com

RGCB opens applications

The Rajiv Gandhi Centre for Biotechnology (RGCB), an autonomous institution of Department of Biotechnology, Government of India, invites applications from GAT-B qualified candidates for its M.Sc. Biotechnology programme for the academic year 2022-24. The course offers specialisations in Disease Biology, Molecular Diagnostics & DNA Profiling, and Genetic Engineering. Applicants must also have 60% aggregate in their Bachelors degree in any branch of Science, Engineering or Medicine. Last date is June 30. Visit https://rgcb.res.in/msc2022.php for details

MindBox launches summer courses

MindBox has announced the launch of its design and coding led summer courses, which include2D Animation, Multimedia Design, Graphic Design Photoshop, Digital Design SketchUp, AI with Python among others. For details, visit https://mindboxindia.com/

Free mock test series for CLAT

Edtech startup Oliveboard has announced a free mock test series for CLAT aspirants (2022) to help them prepare for the exam. The Oliveboard Mock Test is currently live and can be accessed on the website/app until the exam day.

Holberton partners with Jigsaw Academy

The U.S.-based ed-tech company Holberton has partnered with Jigsaw Academy to offer a PG Certificate in Full Stack Development. Holberton will provide the projects, platform, tools and services while Jigsaw will deliver the programme from the Holberton platform and also provide mentoring support to the students.

IET India Scholarship Award

The Institution of Engineering and Technology (IET) has opened applications for the sixth edition of the IET India Scholarship Award, with a combined prize money of Rs 10 Lakhs. The programme aims to reward and celebrate individual excellence and innovation among undergraduate engineering students in ACITE and UGC approved institutes and national institutes in India. For more information, please visit https://scholarships.theietevents.com/#!

Webinar on Management Education

EduCrack will host a webinar at 6.00 p.m. on June 11 to guide students who want to opt for an MBA. Rammohan, Chief Knowledge Officer, EduCrack, will talk about various specialisations and the career options these will lead to. Those interested can join through https://bit.ly/3mw9zaN

Applications open up Rishihood University

Rishihood University (RU) invites applications for its 2022 intake commencing September 2022. At the UG level, the University offers degrees in Design, Visual Arts, Psychology, Education, Leadership among others. Minor specialisations include Computer Science, Law, Media and Sanskrit with electives like Sustainable Development and Creative Writing. At the PG level, programmes include PG Diploma in Leadership, , MA in Interdisciplinary Humanities and Research, MBA, MBA (Entrepreneurship) and M.Design. For details call 1800 120 6631 (toll-free) or visit https://apply.rishihood.edu.in/

WWI entrance exams in June

Whistling Woods International (WWI) has announced the dates for the June round of entrance examinations for the 2022 intake. The last date to register is June 18 and the exams will take place from June21-24. The institute offers degree, post-graduate, and diploma programmes under an agreement with Rajiv Gandhi National Institute of Youth Development (RGNIYD). For details of programmes offered and to apply, visit http://www.whistlingwoods.net

MyCoolGuru launched

MyCoolGuru, a career tech platform, was launched recently. It will offer online and offline courses, list tutors, trainers and counsellors, have notes and questions for exam prep and guidance from industry mentors. Operating through a membership model, it has on boarded 300 tutors and curated over 100 study materials across 25 courses. More details at http://www.mycoolguru.com

Graduation Day celebrated

Saveetha Engineering College celebrated its 15th and 16th Graduation Days earlier this month. Among the dignitaries present were Prof. K.K. Aggarwal, Chairman NBA; S. Suresh Babuji, Joint Director & Head of Office, MSME DI Chennai; Dr. N. M. Veeraiyan, Founder President & Chancellor SIMATS; Dr. S. Rajesh, Director SEC; and Dr. N. Duraipandian, Principal, and the heads of various departments. Over 900 students from the 2019 batch and 830 students from the 2020 batch received their degrees.

Partnerships

Vivekanand Education Societys College of Arts, Science and Commerce (Autonomous) has partnered with GlobalGyan Academy of Management Education to launch new autonomous courses, including undergraduate and post-graduate degrees. Students who have completed their Class 12 exam, from any stream, board and institute, are eligible to apply. For more, visit https://ves.ac.in/

The Karnataka State Education Department and EMBIBE, an AI-powered personalised adaptive learning platform, have entered into a partnership to make available Karnataka Board curriculum in the local language. The objective is to provide students with quality digital education and 3D content for Science and Maths in their language. The platform caters to Classes 6 to 12 and to Engineering and Medical entrance exams.

Crimson Education has partnered with Nxt Venture Labs LLP for EpicQuest, a young entrepreneurial leader in-residence programme. The four-week programme is exclusively designed for Indian high school students; to guide and prepare them via hands-on exposure to effective global business management practices, and entrepreneurial leadership training. EpicQuest will continue till July 4. Each group will consist of 10 students between the ages of 14 to 16 years. For more information, visit https://www.crimsoneducation.org/in/

Lovely Professional University invites applications its B.Tech CSE (AI & Data Engineering) in association with Futurense Technologies. by the university.

Eligibility: 65% aggregate in 10+2 (with Physics, Mathematics and English); qualification in LPUNEST and interview by Futurense Technologies.

Details at https://bit.ly/3HeocZF

Environment Studies course

Augustana University, the U.S., has opened applications of its Environment Studies course for the Spring 2023 intake. The university offers merit-based scholarships of $15,000 to $25,000 for candidates from India, depending on their academic qualifications. For more details, visit https://bit.ly/3aOurHG

IIM-Bangalore in the PIR 2022

IIM-Bangalore features in the top category (Level 5) in the Positive Impact Rating (PIR) 2022. The Indian quartet of IIM-Bangalore, SPJIMR, XLRI, and Woxsen Business School has achieved the highest level of the PIR as Pioneering Schools. The Positive Impact Rating (PIR) is a rating conducted by students and for students to assess the positive impact of business schools.

World Environment Day celebrated

Smiling Tree celebrated World Environment Day along with Leelawanto Saraswati Vidya Mandir School. Students were encouraged to become green warriors, take care of the environment and inspire others to do so.

Noida International University organised a poster making and essay competition on the theme Only One Earth. The aim was to create awareness about climate change and encourage students to take action. Over 70 students from NIUs 12 schools participated.

Orchids The International School has partnered with Citizens Association for Child Rights (CACR), a development partner of UNICEF for WASH, to sensitise its students to environmental issues like waste segregation.

Celebrating diversity

The student-initiated campaign Yaadhum Manamae Yaavarum Kaelir by the Department of Public Relations, Stella Maris College, celebrated its valedictory with a walkathon conducted at Elliots Beach, Besant Nagar. The event was inaugurated by Santhtosh Pratha, actor and mixed martial arts athlete, and S. Nelson, ACP Adyar. Theatre Akku also staged a Tamil play Komaligal that threw light on issues such as gender inequality and intersectional abuse.

Sanskriti team develops electric Buggy

A team of six students (Thokchom, Satish, Monu, Deepak, Jivan, and Akhilesh) from Sanskriti University has developed an electric Buggy, for travelling in sandy and off-road terrain. The team was led by Prof. Anshuman Singh, of the Department of Mechanical Engineering.

View original post here:
News from the world of education - June 10, 2022 - The Hindu

image:Journal focusing on the understanding, prediction, and prevention of acts of violence. Through research papers, roundtable discussions, case studies, and other original content, the Journal critically examines biological, genetic, behavioral, psychological, racial view more

Credit: Mary Ann Liebert, Inc., publishers

In response to the historical devastation of mass shootings in the United States, including the recent mass shooting of 19 innocent children in Uvalde, TX, Violence and GenderEditor-in-ChiefMary Ellen O'Toole, PhDhas issued an immediate call to action for superior gun control laws and legislation.

Weve waited long enough, says Dr. OToole, Editor-in-Chief. This political football must stop. Our children are being killed and the laws must be changed now. We can no longer normalize these behaviors or expect our children to be the victims on the front lines. The research is clear and we must continue to stay educated, relentless, and vigilant in our quest for the future of our country.

In support of Dr. OTooles mission, Violence and Gender is providing free access to the following special issues spanning themes including gun ownership, beliefs about gun control and gun ownership, gun policy, among others.

Special Issue on Gun Violence: Part I

Special Issue on Gun Violence: Part II

Gun violence against our families and our children must be addressed aggressively, echoes Mary Ann Liebert, Publisher of Violence and Gender and president and CEO of the company that bears her name. The current recommendations for gun control reformation are pitiful given the extent of the loss of lives weve seen in schools. Legislators, policy makers, educators, and civilians who refuse to acknowledge the extent of the problem of gun violence should subscribe to Violence and Gender and educate themselves by reading the published, academic research on systematic gun violence in our country. The research is clear and journals such as Violence and Gender couldnt be more important to support real and lasting change. We must remain educated and informed to collectively make the best decisions for our families and our future.

Emphasizing this call to action, Dr. Anna Satterfield, Deputy Editor adds: The US Centers for Disease Control and Prevention (CDC) reported that in the United States in 2020, there were 45,222 firearm-related deaths of which 54 percent were suicides and 43 percent were homicides.Despite various versions of enacted laws to reduce gun violence, laws and regulations continue to miss the mark of what we understand about those that use firearms as weapons.Until we actively enforce a balance between effective gun control laws and effective gun violence prevention/intervention and risk-reduction programs, the United States will remain an outlier in firearm-related deaths compared to other countries.

About the Journal

Violence and Genderis the only peer-reviewed journal focusing on the understanding, prediction, and prevention of acts of violence. Through research papers, roundtable discussions, case studies, and other original content, the Journal critically examines biological, genetic, behavioral, psychological, racial, ethnic, and cultural factors as they relate to the gender of perpetrators of violence. Led by Editor-in-Chief Mary Ellen O'Toole, PhD, Forensic Behavioral Consultant and Senior FBI Profiler/Criminal Investigative Analyst (ret.), Violence and Gender explores the difficult issues that are vital to threat assessment and prevention of the epidemic of violence. Violence and Gender is published quarterly online with Open Access options and in print. Complete tables of content and a sample issue may be viewed on theViolence and Genderwebsite.

About the Publisher

Mary Ann Liebert, Inc., publishersis a privately held, fully integrated media company known for establishing authoritative medical and biomedical peer-reviewed journals, including Cyberpsychology, Behavior, and Social Networking, Journal of Child and Adolescent Psychopharmacology, and Journal of Women's Health. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industrys most widely read publication worldwide. A complete list of the firms more than 100 journals, newsmagazines, and books is available on theMary Ann Liebert, Inc., publisherswebsite.

Violence and Gender

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

Link:
An immediate call to action from the editorial leadership of Violence and Gender - EurekAlert